Drugs / LMB-100
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05375825 | Jan 2024 | Mammastatin, epithelial neoplasm, malignant pleural mesothelioma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT04840615 | Jun → Dec 2021 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT04034238 | Aug 2019 → Dec 2020 | extrahepatic bile duct carcinoma, malignant epithelioid mesothelioma, pancreatic adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03436732 | Feb 2018 → Apr 2019 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT02798536 | Jul 2016 → Jul 2017 | mesothelioma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02317419 | Dec 2014 → Aug 2015 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02810418 | Aug 2016 → Jan 2019 | pancreatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04027946 | Sep 2019 → Jun 2020 | lung adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT03644550 | Dec 2018 → Aug 2020 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMB-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04034238 ↗ |
| Known as | Anti-msln-pe24 cfp lmb-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297777 ↗ |
| Known as | RG-7787 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297777 ↗ |
| Known as | RO6927005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317419 ↗ |
| Action | Deplete | “After binding to mesothelin on tumors, LMB-100 attacks and kills cancer cells.” NCT02798536 ↗ |
| Modality | Protein / enzyme biologic | “LMB-100 is a novel recombinant anti-mesothelin immunotoxin” NCT02798536 ↗ |
| Route | Intravenous | “RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).” NCT02317419 ↗ |
| Target | EEF2 | “Elongation factor 2 disrupting agent” CHEMBL4297777 ↗ |
| Target | MSLN | “LMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin” PMID 38706610 ↗ Apr 2024 |